Certis Oncology

CertisAI™ is the first and only commercially available drug response and synergy platform that can predict therapeutic efficacy — requiring just a small molecule as input. This pan-cancer solution can accelerate drug discovery and companion diagnostics development by leveraging artificial intelligence and machine learning to support early decision-making. With predictions generated by in silico models, translational oncology researchers can effectively replace many discovery screening studies with computer-aided insight. CertisAI can be employed to inform lead candidate selection, model selection, biomarker development, combinatorial strategies, and more.

CertisAI is 90%+ accurate for monotherapy predictions and 80%+ accurate for combination therapies. Unlike other companies with emerging AI technologies, Certis uses clinically relevant orthotopic PDX (O-PDX models) to validate predictions and accelerate machine learning processes.

AI-Enabled Services:

• Research services that use machine learning (ML) algorithms

• Data services that use ML, LLMs or NLP